BioMarin Pharmaceutical and Serono Form Strategic Alliance

BioMarin Pharmaceutical and Serono announced that they have formed a strategic alliance for the further development and commercialization of two BioMarin product candidates, Phenoptin (sapropterin hydrochloride) and Phenylase (phenylalanine ammonia lyase). Both products have shown potential in the treatment of phenylketonuria (PKU), and there is preliminary clinical evidence that suggests that the active ingredient in Phenoptin, a synthetic form of the naturally occurring enzyme cofactor 6R-BH4, may also be useful in the treatment of other serious diseases, including diabetes and cardiovascular diseases.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20068820&full=1)